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Abstract
Although the spread of drug resistance and the influence of climate change on malaria are most often considered
separately, these factors have the potential to interact through altered levels of transmission intensity. The influence of
transmission intensity on the evolution of drug resistance has been addressed in theoretical studies from a population
genetics’ perspective; less is known however on how epidemiological dynamics at the population level modulates this
influence. We ask from a theoretical perspective, whether population dynamics can explain non-trivial, non-monotonic,
patterns of treatment failure with transmission intensity, and, if so, under what conditions. We then address the implications
of warmer temperatures in an East African highland, where, as in other similar regions at the altitudinal edge of malaria’s
distribution, there has been a pronounced increase of cases from the 1970s to the 1990s. Our theoretical analyses, with a
transmission model that includes different levels of immunity, demonstrate that an increase in transmission beyond a
threshold can lead to a decrease in drug resistance, as previously shown [1], but that a second threshold may occur and lead
to the re-establishment of drug resistance. Estimates of the increase in transmission intensity from the 1970s to the 1990s
for the Kenyan time series, obtained by fitting the two-stage version of the model with an explicit representation of vector
dynamics, suggest that warmer temperatures are likely to have moved the system towards the first threshold, and in so
doing, to have promoted the faster spread of drug resistance. Climate change and drug resistance can interact and need not
be considered as alternative explanations for trends in disease incidence in this region. Non-monotonic patterns of
treatment failure with transmission intensity similar to those described as the ‘valley phenomenon’ for Uganda can result
from epidemiological dynamics but under poorly understood assumptions.
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Introduction
Evolutionary change is one main challenge to the understanding
and prediction of climate change impacts on biological systems.
Environmental and evolutionary drivers of biological change are
likely to interact in ways poorly understood. One area where this
interaction has the potential to act on relatively fast time scales is
the dynamics of vector-transmitted diseases. These diseases, such
as malaria, are especially sensitive to changes in environmental
conditions. Climate change expressed through changes in tem-
perature and precipitation influences habitat suitability and can
potentially shift the geographical range of malaria. Warmer
temperatures accelerate physiological processes of the mosquito
vector, leading to increased activity such as biting rate, growth,
development and reproduction. Extreme temperatures may also
decrease survivorship of vectors, leading to a convex relationship
between temperature and mosquito performance. Physiological
processes of parasite development within the vector are also
affected by temperature levels in a nonlinear way [2–5]. In
particular, temperature plays a key limiting role on malaria at the
edge of the altitudinal distribution of the disease, in highland
regions, where the parasite is not likely to complete development
during the lifetime of its vector.
Climate change and drug resistance have been typically
addressed as independent drivers of malaria trends, and have
been considered as alternative explanations for the exacerbation of
the disease in East African highlands [6–8,4]. This was sensible
when analyses of temperature records showed no evidence for a
trend in climate variables [6]; more recent re-analyses of these
records now indicate that temperature trends are present [8,9],
also in local temperatures [9], raising the possibility of synergistic
interactions between warmer temperatures and drug resistance, in
the larger context of pathogen evolution under changing environ-
mental conditions. In one direction, the non-independence of
these factors is trivial: we clearly do not expect to see any increase
in transmission and prevalence when drugs are available and
effective. Thus, the failure of treatment is a pre-requisite for an
effect of climate change in areas with access to treatment by
effective drugs. There are excellent examples of comparisons
between locations with different drug policies, including the
introduction of new, effective, drugs with clear contrasts in the
occurrence of epidemics (e.g., [7]. It is the opposite direction that
interests us here: the influence of higher transmission, driven by
climate change, on the spread of drug resistance.
Numerous modelling studies have addressed the interplay of
transmission intensity and drug resistance from a population
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genetics perspective (see: [10–13]). Less attention has been given to
how the population dynamics of the disease modulates this
interaction (e.g., [1,14,15]). Among these studies, two recent
epidemiological models propose that low, rather than high,
transmission would favor the spread of drug resistance [1,14].
These studies also emphasize the importance of immunity
considerations. In particular, Klein et al. (2008) show that clinical
immunity can act as a refuge for the wild type, non-resistant,
strain, and in so doing, oppose the emergence of drug resistance at
high transmission levels for which population structure shifts
towards providing such a refuge. This mechanism was proposed as
an explanation for the empirical observation of the de novo
evolution of drug resistance in areas of low transmission intensity.
Throughout this paper, our focus is not on the de novo evolution of
drug resistance, but on the invasion and spread of resistance when
introduced in a population (for recent results on the former, see
[12,13]). While the former is a rare (albeit important) event, the
latter affects the prevalence of drug resistance in large regions of
the globe [16].
We specifically examine the role of immunity in the evolution of
drug resistance further, with a particular focus on conditions that
influence the existence of thresholds in the selective advantage of
drug resistance as a function of transmission intensity. We extend
the analyses of Klein et al. (2008) in three ways. First, we consider
an epidemiological model that integrates multiple levels of
immunity within a population of hosts. The approach we use
stems from the idea that transmission intensity structures a local
community into a series of immunity classes, such that under
different climatic settings, the distribution of hosts between
immunity classes varies. The model is constructed as a multi-
stage SIS model with different levels of immunity as a function of
exposure, and is an extension of the previously proposed two-stage
model [1]. Analytical analysis and simulations demonstrate that at
low transmission settings changes increase in transmission acts to
encourage the spread of drug resistance, and that further increase
in transmission beyond a threshold can lead to a decrease in drug
resistance, as previously shown by Klein et al. (2008), but that a
second threshold can occur, where further increases in transmis-
sion lead to the re-establishment of drug resistance. This work
identifies the main assumptions required for the existence of both
thresholds, and therefore, for the existence of a non-monotonic
pattern in which the fitness of the drug resistance parasite first
increases, then decreases, and increases again. A second modifi-
cation of the original two-stage model is also theoretical, intro-
ducing in a phenomenological way, the observation that parasite
antigenic diversity increases with transmission. This is shown to
move the first threshold to higher values of transmission, making it
a moving target and hence extending the range of transmission
intensities that increase the fitness of the drug resistant parasite.
A third extension adds to the two-stage model for transmission
in humans, a mosquito submodel for the population dynamics of
the vector as a function of observed temperatures and rainfall.
With this model, we seek to determine where the system lies,
relative to the first threshold, in an East African highland as
temperatures increase from the 1970s to the 1990s. Increases in
transmission intensity below this point would have promoted the
spread of drug resistance. To this end, we consider a time series of
malaria cases from a tea plantation in the Kenyan highlands that
has been at the center of retrospective malaria studies [5,7,8,17]
Although it is in these regions at the edge of the geographical
distribution of the disease, where altitude limits transmission, that
effects of climate change are expected to be most apparent, the
underlying and dominant causes for larger and more frequent
epidemics from the 1970s to the 1990s are not yet clear [6–8,18,19].
Climate change is one among several factors that have been
proposed as the driving forces responsible for the exacerbation of
the disease, including the spread of anti-malarial drug resistance,
declining health services provision, reduced vector control and
increased host abundance [6,7]. Although chloroquine (CQ)
resistance first appeared in Kenya in the late 1970s, in 1985
parasites were still found to be sensitive to the drug in a highland
district adjacent to this tea plantation [20]. By 1996, however, the
drug was unable to clear approximately half of the clinical infections
in children in the Kericho hospital [21]. Interestingly, the
emergence of drug resistance in the Kenyan highlands overlaps in
timing with the rise in temperatures over the past three decades
[8,9], making it difficult to consider these drivers independently.
Our results suggest that the observed temperature trend has been
sufficient to alter the epidemiological structure of the population,
and that in doing so, this trend would not have acted independently
from drug resistance.
We end with implications of our findings in relation to empirical
patterns, including the ‘valley phenomenon’ described for CQ in the
Uganda highlands, where treatment failure was found to be higher
in areas of low and high transmission, and at it’s lowest at inter-
mediate transmission areas [22–24]. We also discuss epidemiolog-
ical assumptions identified by our analyses, and open questions on
key aspects of parasite diversity of relevance to these assumptions
that are still poorly understood, at the interface of molecular studies,
within-host dynamics, and between-host transmission.
Results
Our initial model is based on the observation that individuals
living in areas of endemic P. falciparum develop immunity to
malaria with age and exposure [25–27]; as levels of immunity are
higher, there is a decline of parasite density in the blood [28]
which is assumed to lead to milder clinical symptoms [25,26,29,30],
and to either lower probabilities of transmission to mosquitoes
[31,32] or alternatively, to higher transmissibility of asymptomatic
carriers [33]. Thus, given that all infected individuals contribute
(at least to some extent) to the general pool of the force of infection
[34], but that for different immunity classes the selection pressure
acting for or against drug resistance can differ, it is possible that
under different transmission intensities drug resistance may or may
not spread.
The model is constructed as a multi-class SIS model, with levels
of immunity increasing from class to class (see diagram in Figure 1).
The acquisition of immunity expresses itself in several ways. When
immunity is low, infected individuals usually suffer from severe
clinical symptoms, leading to a higher likeliness of drug treatment.
However, as immunity is gained, these symptoms become milder
and the use of drug treatment declines. It is assumed that as a
consequence of the lower levels of parasitaemia that accompanies
higher levels of immunity, infectivity to mosquitoes decreases.
We consider that an infection can take one of two forms; the
infection is either by a drug sensitive parasite, the wild type, or by a
drug resistant parasite. We assume a fitness cost accompanies
resistance [35–37], which we assume to occur in the clearance rate
of an infection, such that resistant parasites are naturally cleared
more effectively from the host than the wild type. Note however,
that the fitness cost accompanying resistance may occur in one or
in several other stages of the parasites’ life cycle, as discussed later
on. Our modeling approach is an extension to that offered by
Klein et al. (2008), with the added realism of multiple classes to
approximate a continuum in levels of parasitemia and immunity.
A detailed description of the model and the related equations is
given in the Materials and Methods section.
Resistance and Climate Change
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Model simulations show that at high levels of transmission
intensity, or vectorial capacity, the general prevalence of infection
in the population is higher, and the distribution of individuals
tends to be accumulated in the higher immunity classes (see
Figure 2). As vectorial capacity increases, individuals are re-
peatedly bitten, which leads to higher rates of re-infection. The
individuals that are rapidly re-infected will stay longer in an
infected state. This leads individuals to gain higher levels of
immunity, as well as insuring that the immunity they have gained
is less likely to be lost. In return, larger fractions of the population
exhibit milder clinical symptoms, and the relative drug use is
generally lower. It is important to note that as the distribution of
hosts leans towards the higher immunity classes, it is only the
relative fraction of treated individuals which starts dropping, while
the overall drug treatment in the population may continue to
increase with the general rise in prevalence. This is in contrast to
earlier notions that the decrease in drug pressure in high
transmission areas is due to a general decrease in drug use and
not a relative one [12,38].
As expected, our results show that the resistant parasite has a
clear advantage over the wild type when high levels of drug
treatment are being applied. In this regime, if the drug pressure is
high enough in relation to the fitness cost of resistance, the wild
type is cleared from the infected hosts at a faster rate than the
resistant parasite. Thus, the resistant parasite has the opportunity
to spread more effectively throughout the host population, leading
to the extinction of the wild type. However, as demonstrated in
Figure 2, when vectorial capacity increases even further, larger
fractions of the population accumulate in higher immunity classes
for which clinical symptoms are milder. This leads to a drop in the
relative level of drug treatment per infection, such that the drug
pressure on the parasite decreases down to a threshold where the
fitness cost of resistance is more dominant than the benefit of being
resistant. At this point, the duration of infection by the wild type is
effectively longer than that of the resistant, leading to the
extinction of the resistant parasite. These results are similar to
those obtained by Klein et al. 2008 based on their two-class SIS
modeling approach. We ask next under what conditions, if any,
would the wild type refuge provided by clinical immunity be lost
for higher levels of transmission, restoring the advantage of
resistance.
We find that one way to obtain this pattern in the multi-class
SIS model, is to consider that the duration of infection is longer as
immunity increases. Lower levels of parasitemia in the blood, as
well as the mild clinical symptoms, may decrease the severity of the
immune response, thus allowing infections to last longer. Evidence
for this possibly counter-intuitive assumption is discussed in the
Discussion section and implications of releasing this assumption
are considered later in this section. When it applies, a second
Figure 1. An illustration of the structure of the model. Immunity classes are portrayed in an escalating order from left to right, such that
subscript i= 1 represents hosts with the lowest level of immunity, and subscript i= n represents hosts with the highest level of immunity. In each
immunity class individuals are either susceptible or infected. If the duration of infection within a given class is relatively short, individuals recover and
return to the susceptible state within their immunity class. When the duration of infection is extensive, or alternatively, if individuals are repeatedly re-
infected spending large fractions of time in the infected state, it is assumed that this prolonged cumulative exposure leads to a higher level of
immunity, moving these individuals to the next immunity class. However, if individuals in an immunity class remain susceptible for a long duration
time, without renewed exposure to the disease during this time, they loose their current level of immunity and move back down the previous
immunity class. The structure of the model captures the idea that acquired immunity gradually weakens in the absence of exposure to infection, but
quickly strengthens itself if additional exposure accurse within a given time frame from the previous infection as discussed by [60]. Black represents
susceptibles, blue sensitive wild-type and red resistant.
doi:10.1371/journal.pone.0013588.g001
Figure 2. Fraction of the population in the different immunity
classes as a function of vectorial capacity for a simplified three
class model (the x-axis is given in log scale). The orange line
represents the fraction of hosts in class 1, the green line represents the
fraction in class 2 and the blue line represents the fraction in class 3. For
low levels of vectorial capacity the majority of the population is in the
lowest immunity class, and as vectorial capacity increases, individuals in
the population gain higher levels of immunity.
doi:10.1371/journal.pone.0013588.g002
Resistance and Climate Change
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threshold can exist, where an additional turnover takes place (see
Figure 3). Specifically, when the duration of infection is sufficiently
longer in the higher immunity classes, the fitness cost of the
resistant parasite becomes negligible in comparison to the drug
pressure that is still being applied on the population, even if at very
low levels. In Figure 3 we demonstrate by simulation a case in
which there are two such turnovers; from a regime in which the
resistant parasite dominates the population due to strong drug
pressure, to a regime in which the wild type takes over due to the
fitness cost for the resistant parasite, and back to a regime in which
the resistant parasite dominates the population again, due to a
natural increase in the duration of infection. Formal analysis of this
result is given in the Materials and Methods section, where the
effective reproductive number (R0) of the wild type and resistant
parasites is calculated.
The non-monotonic pattern of resistance spread with transmis-
sion intensity in Figure 3 can be modified by varying the values of
three key parameters in the system: (i) the levels of treatment in the
population, (ii) the fitness cost on the resistant parasite and (iii),
the natural duration of infection (see Materials and Methods,
necessary conditions in a 3-class model, as well as Figure S1-1 and
S1-2 in Supporting Information S1 for 2D projections of varying
costs of resistance and treatment levels as a function of vectorial
capacity). In other words, the existence of the above-described
thresholds depends on a sufficiently high (intermediate) cost of
resistance and on a sufficient level of drug treatment. The fitness
cost of resistance is likely to vary for different anti-malarial
drugs [35].
In the context of our model so far, a non-monotonic pattern
with drug resistance parasite favored at low and high transmission
intensities, and the sensitive parasite at intermediate values, can
only arise under the assumption that the duration of infection
increases with immunity level. (We note, however, that the first
threshold does not require this assumption, and occurs also under
a constant [1] or decreasing duration.
We specifically note that both our model and that of Klein and
colleagues, implicitly consider that the rate at which immunity is
boosted and lost by re-exposure is constant for all levels of
transmission intensity. This ignores the role of strain (antigenic)
diversity in the acquisition of immunity, which differs between
regions, and under different transmission intensities. In endemic
areas, where vectorial capacity is high, strain diversity is also ex-
pected to be higher [39,40], and so the acquisition and main-
tenance of immunity in these areas is lower than it would be in
areas of low diversity. We therefore consider that hi, i.e., the rate
at which immunity is gained, is a function of parasite diversity.
Thus, the rate of moving from one class of immunity to the next
depends on the level of parasite diversity, and therefore, in the
model itself on transmission intensities.
Figure 4 illustrates the role that strain diversity may have on the
establishment of anti-malarial drug resistance. The expected
threshold ( fc) for a two-class model is fc~
A
AzB
, where A and
B are positive and as defined in the Materials and Methods section
(Thresholds in a two class model). Hence, when the fraction of
the population in the second immunity class ( f2) is below this
threshold ( fc), the resistant parasite out-competes the sensitive one,
and when the fraction is above this threshold, the sensitive parasite
out-competes the resistant. For different diversity levels, we find
that the lower the diversity, the lower the vectorial capacity at
which the threshold is crossed. Hence, the first threshold described
in our analysis (as well as in [1]) can become a moving target, shifting
towards higher values of transmission intensity as diversity also
increases. This would make such threshold more difficult to reach
Figure 3. Non-monotonic pattern of resistance spread with
transmission intensity. The fraction of infection in the population as
a function of vectorial capacity for a simplified three-class model (the x-
axis is given in log scale). Red indicates infection by the resistant
parasite; blue, by the wild-type parasite. For very low levels of vectorial
capacity, both parasites do not persist (the effective reproductive ratio,
Rw and Rr, of the wild-type and resistant, respectively, is smaller than 1).
With the increase of vectorial capacity, the Rr of the resistant parasite is
larger than that of the wild type, Rw, making it dominate the infected
population (region I, marked in red). At intermediate vectorial
capacities, a first threshold is observed where the wild type parasite
out-competes the resistant one (region II, marked in blue). At high
levels of vectorial capacity, a second threshold is observed where the
resistant parasite out-competes the wild type (region III, marked in red).
Parameters are given in Table 1.
doi:10.1371/journal.pone.0013588.g003
Figure 4. Fraction of clinically immune individuals as a function
of vectorial capacity for a two-class model scenario (the x-axis
is given in log scale). Results of increasing strain diversity are plotted
in escalating shades from top to bottom (gain of immunity 1=h= 5
years, 1=h= 10 years and 1=h= 20 years, respectively). Threshold levels
at which resistance is out competed by wild type, fc~A= AzBð Þ, are
marked by horizontal gray lines (see definition of A and B in the
Materials and Methods subsection, Thresholds in a two class model). For
lower strain diversity, immunity is rapidly gained in the population and
the threshold, fc, is low. Alternatively, when strain diversity is higher,
immunity is gained more gradually, and the threshold is higher (Similar
results are obtained for multiple classes).
doi:10.1371/journal.pone.0013588.g004
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with the population remaining in a regime where drug resistance is
favored as transmission intensity increases.
Because Kericho is in an area of low transmission intensity, at
the edge of the altitudinal distribution of the disease, we can
consider the simpler version of the model, with only two levels of
immunity, focusing on the first threshold. This reduces the number
of parameters and allows us to extend the model to consider the
vector’s dependence on temperature. We note that in this version
of the model we do not specify a priori how the duration of
infection varies with level of immunity. The force of infection is
specified by coupling the model for the human host to a vector
sub-model describing the abundance of mosquitoes in four classes,
corresponding respectively to larvae, uninfected, exposed and
infected adults. The full set of equations for the coupled human-
mosquito model are given in Supporting Information S2. The
parameters of this coupled model are fitted to the malaria time
series from 1970 to 1985 only, using as covariates local mete-
orological time series for rainfall and temperature [41]; see also
Supporting Information S2). Importantly, consideration of this
time period, allows us to fit the model with only the wild-type
strain. The fitted parameters and the observed temperature data
are then used to simulate the model forward in time to quantify the
consequences of the observed trend in temperatures of approxi-
mately one degree (see Figure 1 in [9]). We specifically address
whether the resistant strain would have a higher fitness and
therefore be able to invade the system as temperature increases.
Details on the method of parameter estimation, based on maxi-
mum likelihood estimation via a genetic algorithm, can be found
in Alonso et al. (in review) and in Supporting Information S2. It is
important to note that given the complexity of the model, our
search of parameter space gives us not one but a family of
parameter sets with equivalent likelihoods. This set reflects the
uncertainty in the estimated parameters, especially given our
reliance on the first 15 years only, which exhibited weak seasonal
transmission and therefore provide limited information. We
generate based on this set, a family of simulations whose behavior
is represented in Figure 5a. Despite the uncertainty, this figure
shows a clear tendency of the population in the clinically immune
class to increase from the 1970s to the 1990s, concurrent with an
increase in the size of epidemics. Provided the first threshold has
not yet been crossed, these changes would imply initially an
increase of the effective R0 of the resistant strain, at a faster rate
than that of the wild-type, and therefore, an increasing ability of
the resistant strain to invade and displace the resident wild-type
(see Figure S3-1 in Supporting Information S3) leading to a
synergistic effect of climate change and drug resistance increasing
the number of symptomatic cases of malaria. We note, however,
that the difference between the respective R0 of the two strains is
not monotonic below this threshold, and that after the initial
increase (synergy), this difference reaches a maximum and then
decreases as vectorial capacity rises further (see Figure S3-1 in
Supporting Information S3).
Whether or not the system has crossed the threshold depends on
two unknown quantities, namely the cost of resistance and the
proportion of the recovery rate that is due to treatment (see
Supporting Information S2). We can consider different combina-
tions of these two quantities and obtain the fraction of simulated
solutions that have not crossed the threshold at a given point in
time. This fraction quantifies the likelihood that the resistant
parasite can invade the system and spread, given the uncertainty in
the fitted parameters. Figure S2-1 (Supporting Information S2)
shows a general tendency for this fraction to decrease in the 1990s.
However, for high treatment levels and low to moderate costs of
resistance, this probability remains above 0.5, implying that
clinical immunity has not increased enough to tip the balance in
favor of the wild-type by creating a refuge, an that the majority of
the solutions have not crossed the threshold. It is also possible for
the solutions to cross the threshold back and fourth intermittently
Figure 5. Simulated trajectories of the two-class model with the force of infection driven by a local temperature and rainfall records
through a sub-model for the dynamics of infection in the mosquito vector. Parameters of the coupled mosquito-human equations were
obtained by fitting this model to the monthly time series of confirmed cases from the hospital serving the tea estates of the Brooke Bond Farms in
Kenya (elevation 1780–2225m) from 1970 to 1985 only, a period of low incidence when drug resistance was not apparent in this region. The search of
parameter space produces sets of values, reflecting the uncertainty in their determination given the data (see Supporting Information S2).
Simulations of the model for the different parameter sets and with the observed temperature, produces the range of behaviors illustrated in grey for
the fraction of the population in the clinically-immune class (5% and 95% percentiles of the distribution for the predicted fraction of hosts in the
second immunity class at each time. The horizontal dashed line represents the threshold fraction of hosts in the second immunity class (fc) below
which drug resistance is favored, and demonstrated in black is a realization with fitness cost of 0.5, as explained in Materials and Methods, Thresholds
in a two class model. In red is the time series of the number of observed cases.
doi:10.1371/journal.pone.0013588.g005
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as vectorial capacity varies seasonally and interannually. This
occurs at intermediate values of the cost of resistance and, reflects
a regime in which vectorial capacity is not high enough yet to
provide a sustained refuge for the wild type.
That the system is not likely to have crossed the threshold that
favors the wild type, tells us about invasion of the resistant strain
(technically that we are in a region where its reproductive number
is higher than that of the wild-type), but does not tell us whether
this advantage has become larger with the increase in transmission
intensity. This is because, as we noted before, this difference is
non-monotonic for values of transmission intensity below the
threshold. In Figure S2-2 (Supporting Information S2) we consider
this specific difference and illustrate the tendency for this dif-
ference to increase from the 1970s to the 1990s provided treat-
ment levels were sufficiently high.
Discussion
Our findings underscore that drug resistance and climate change
can interact through the effects of warmer temperatures on
transmission intensity. The non-monotonic pattern described here
as the result of two thresholds in the selective advantage of resis-
tance (see Figure 3, and pattern a in Figure S1-1 in Supporting
Information S1), resembles the ‘valley phenomenon’ observed for
CQ resistance in Uganda, where treatment failure was found to be
higher in areas of low and high transmission, and at its lowest in
areas of intermediate transmission [22–24]. The epidemiological
model can also explain other patterns such as a monotonic increase
in drug resistance as a function of transmission intensity (see pattern
e in Figure S1-1 in Supporting Information S1) resembling the
observations found for sulphadoxine-pyrimethamine (SP) resistance
in the same region [22–24]. Key parameters determining the
existence of the two different thresholds as transmission intensity
increases are the cost of resistance for the different drugs and the
levels of drug treatment. We have also shown that increases
in parasite diversity with transmission intensity can increase the
value of the first threshold, and therefore, delay or eliminate the
emergence of a refuge for the wild type at high transmission.
The question of whether drug resistance is more likely to spread in
areas of low transmission intensity potentially carries major impli-
cations on control measures such as the use of bed nets and
insecticides. Only under a positive association, vector control
strategies would work hand in hand leading both to a decline in
the general prevalence as well as limiting the spread of drug resistance
keeping drug treatment effective. Klein et al. (2008) discuss the
consequences for malaria control, especially in high transmission
(endemic) regions, as the result of the emergence of a wild-type refuge
at high transmission intensities. However, further examination of
their two-stage immunity model and consideration of multiple levels
of immunity shows here that the existence of a refuge (and its
associated threshold) depends on a number of important consider-
ations that require quantification for specific settings. In particular, it
is possible for a relatively small reduction in transmission intensity to
favor the wild type, but for an even larger reduction in transmission
intensity to give rise to the opposite effect. Anti-malarial drug
resistance could be inhibited in the early stages of control programs,
only starting to resurge as the disease nears eradication.
From the perspective of climate change, the interplay of
transmission intensity with the evolution of drug resistance is
potentially most important for epidemic malaria in highland areas
at the edge of the distribution of the disease, where temperature
has limited transmission in the past. Regions previously considered
epidemic in the highlands of Kenya have shown a tendency
towards more seasonal outbreaks, with signatures of more endemic
behavior in the age distribution of cases [6,42]. A decrease in the
adult-to-child ratio of inpatients in the mid-1980s reflects an
increase in the levels of immunity in the population [6,42]. These
observations are consistent with our results for the Kericho tea
plantation showing an increase in the fraction of the population
with clinical immunity from the 1970s to the 1990s. We note that
this increase is in our projections for the 1990s purely the result of
the observed increase in temperatures. The implication is that
warming was sufficient to produce a significant shift in the
epidemiological structure of the population. Other factors must
also be at play, however, since the concomitant increase in cases
produced by our model simulations is significant when compared
to the no trend scenario, but is typically smaller than that of the
observed cases [41]. To the left of the first threshold, the increase
in transmission intensity from the low values in the 1970s is likely
to have been accompanied, at least initially, by an increase in the
effective reproductive number of the resistant phenotype at a faster
rate than that of the wild-type strain. It is in this sense, that to the
left of this threshold, warmer temperatures can act synergistically
with drug resistance.
This raises the question of whether the temperature trend was
sufficient to push the system across the first threshold identified in
the two-class model for which the resistant phenotype is no longer
favored and a wild-type refuge is established. This is not supported
by the reported 50% treatment failure for children in the hospital
in the 1990s, which indicates the presence of drug resistance in this
region [7]. The location of the system relative to this threshold
depends in the epidemiological model on the levels of treatment
and costs of resistance for chloroquine. Treatment levels are likely
to be high in this tea plantation where the hospital has provided
health care for the population of workers and its dependents.
Under this scenario, our results suggest a high likelihood that the
threshold has not been crossed. Very high costs of drug resistance
would have been required for the wild-type refuge to emerge under
high treatment levels.
Our analysis considered the long-term outcome of the compe-
tition of the two parasites, addressing whether or not the resistant
parasite would be able to invade if transmission intensity was kept
constant at its value for each month. Thus, seasonality and non-
stationary temperature conditions are considered for the population
dynamics of the resident strain, with the effective R0 of this strain
evaluated at the equilibrium of the model for those conditions at
each time, but not for the transients of competition between the two
strains. It is an open question whether such transient dynamics are
involved in the seasonal variability in the frequency of the resistant
genotype observed for other epidemic regions in desert regions of
Africa [43,44]. We are not aware of similar observations for
highland regions but sampling resistance levels, and not just cases, in
surveillance efforts over time would allow a better parameterization
of epidemiological dynamics and a better understanding of drug
resistance in the context of variable transmission.
Epidemiological parameters were obtained here by fitting the
model, with only two classes, to the first part of the malaria time
series when incidence was low and drug resistance was not
apparent in this region. It is important to note that the model was
not fitted to the whole time series, and in particular to the
epidemics of the 1990s during the period of higher incidence,
because our aim was not to consider a priori that the observed
temperature trend was the only factor responsible for the observed
exacerbation of the disease. It would have been trivial to fit the
model to the whole time series; however, this would have also been
completely uninformative in a place where many other factors,
other than temperature, are known to have varied concurrently
with temperature. We used the model to ask instead what would
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have been the possible effect of the observed temperature trend in
the 1990s, given values of the transmission intensity and other
parameters consistent with the observed data in the 1970s and
beginning of the 1980s.
It is also important to mention that our results for Kericho do
not imply that the introduction of a new drug would be ineffective.
In fact, the introduction after the 1990s of new drug treatments,
other than chloroquine, has been proposed as one main reason for
the decrease in malaria cases in more recent years [7]. Other
control measures including insecticide spraying have also been
implemented in the region.
The epidemiological models considered here complement theo-
retical studies based on population genetics, and the clear importance
of epidemiological considerations related to immunity here and in
other recent studies [1,14] supports the recent call for models that
merge population dynamics and population genetics [45]. Field
evidence relating the transmission intensity to the spread of drug
resistance remains limited, with observations leading to contradicting
interpretations [22–24,46,47]. This is also the case on the theore-
tical side, with previous mathematical models based on population
genetics suggesting a positive association [10,48], a negative associ-
ation [49–51] or a concave association [13]. Critical assumptions
in these models relate to the number of genes encoding resistance
[10,11,52,53], the existence of intra host dynamics [12] and a direct
tie between transmission intensity and recombination rate via the
level of clonal multiplicity [13]. Further empirical work is needed to
test these assumptions [13], especially at the interface of within-host
and between-host dynamics.
Only the existence of a second threshold, for which the
advantage of resistance is restored at high transmission intensity, is
dependent in our theoretical results on the assumption that the
duration of infection increases as individuals acquire higher levels
of immunity. Although most epidemiological models assume the
opposite relationship, there is little empirical evidence on the effect
of immunity on the duration of infection, despite the central
relevance of this parameter to vectorial capacity and the basic
reproductive number of the disease, as pointed out by [54]. There
is also considerable uncertainty in the related pattern between the
duration of infection and age (see for example, Table S2 row IM10
in supplement of [14]). Because earlier studies demonstrating
shorter infected periods with age were based on analyses of se-
quential blood slide data [55,56], these were limited by the pro-
blem of discriminating between successive new infections and
persistent ones [57,58]. A more recent statistical analysis of
infections characterized by molecular methods at the level of the
parasite’s genotype supports the opposite pattern of an increase in
the duration of infection with age [58]. Indirect evidence for this
pattern was also found in comparisons of age-prevalence curves
between dry and rainy seasons, and in a malaria transmission
model that explores the biological basis for acquired immunity and
differentiates ‘anti-disease’ and ‘anti-infection’ protection [57].
Ultimately, the relationship between immunity and epidemiolog-
ical parameters will be elucidated by a better understanding of
antigenic strain structure, within-host antigenic variation, and
strategies for immune evasion of the parasite.
We have assumed that the fitness cost accompanying resistance
occurs in the clearance rate of an infection, such that resistant
parasites are naturally cleared more effectively from the host than
the wild type. It is however possible, for the fitness cost of
resistance to occur in one or in several other stages of the parasites’
life cycle, resulting for example in impaired within-host growth, or
lower transmission probabilities. It is straightforward to extend our
analyses to consider the robustness of the valley phenomenon to
these variations (see Supporting Information S4). Interestingly, an
increase or decrease in the transmission probabilities (ci ’s) between
the immunity classes plays no role on the conditions for the valley
phenomenon. Moreover, when there is no fitness cost on the
probability of transmission, the clearance rate of the resistant
parasite must be assumed to decrease with gain of immunity. This
is the case, however, regardless of whether the cost of resistance
decreases or increases clearance rate. Finally, if the fitness cost acts
on transmission probabilities, then the valley phenomenon may
emerge even when there is no reduction in clearance rate between
the immunity classes (of both the resistant and the wild type).
These considerations emphasize the need for a better under-
standing of the mechanisms operating in the within-host dynamics
of the pathogen that underlie specific epidemiological assumptions.
For example, a fitness cost that impairs within-host growth rates
may also lengthen the duration of resistant infections, or change the
transmission probabilities. A different epidemiological consideration
concerns the duration of infection with level of immunity. The
relation between these two effects on clearance rates is not straight-
forward, and ultimately only an empirical understanding of within-
host mechanisms can elucidate this, including the possibility of
inconsistent hypotheses. We have considered here a particular
model structure motivated by the previous work by Klein et al.
(2008), to represent the acquisition of clinical immunity and dif-
ferent, associated levels of parasitemia. Future work should examine
the robustness of our results to model structure, as the represen-
tation of these complex biological phenomena in a disease such as
malaria remains a challenge.
As shown by the detailed age-structure model of Pongtavornpi-
nyo et al. (2008), empirical data on the duration of infection and
other functions relating immunity to central epidemiological para-
meters are critical to models that consider the spread of resistance,
especially for new drugs and multi-drug treatments (such as ACT).
Empirical studies that consider asymptomatic individuals and
molecular methods of parasite detection would be most useful for
these purposes. Additional field data on temporal and spatial
patterns of drug resistance would be clearly invaluable; their
interpretation is likely to require consideration of an epidemio-
logical perspective at the population level.
Materials and Methods
Human dynamics
We assume that there are three possible states in each immunity
class; susceptible, infected with a sensitive ‘wild type’ parasite, and
infected with a resistant parasite. The human population densities
of the different states of each class are denoted as Si, Iw,i, Ir,i,
where the subscript i= (1,…,n) denotes the immunity class. The
subscripts w is used to denote an infection by a ‘wild type’ parasite,
while the subscripts r is used to denote an infection by a resistant
parasite. The natural birth and death rate are assumed to be equal,
such that the population birthrate B is equal to the per capita
death rate of the human population, m. Disease induced mortality
is allowed to vary between immunity classes and we assume that
mw,i~mr,i or all immunity classes.
Vectorial capacity
As in Klein et al. (2008), model notation follows [3,59]; m
denotes the number of mosquitoes per human and a the human
feeding rate (the number of bites on humans per mosquito per
day). The instantaneous death rate is g, and g is the number of
days required for sporogony. Vectorial capacity, V, i.e., the
number of infectious bites by a mosquito over its lifetime, is then
given by the formula V~ma2e{gg

g. The fraction P of bites on
humans that infect a mosquito depends on the transmission
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probabilities of the different immunity classes, ci, and the frac-
tion of infected hosts in each immunity class, such that
P~
Pn
i~1
ci Iw,izIr,ið Þ. The sporozoite rate, i.e., the fraction of
infectious mosquitoes, is defined as aPe{gg= gzaPð Þ. The
entomological inoculation rate, EIR, i.e., the number of infectious
bites per person per day, is calculated as the product of the human
biting rate, ma, and the sporozoite rate (aPe{gg= gzaPð Þ). The
force of infection, or happenings rate, h, is defined as bEIR, where
b, the infectivity rate, measures the fraction of bites in humans that
produce a patent infection. It follows that h~bVP= 1zsPð Þ,
where s~a=g is the stability index, i.e., the number of bites on a
human per vector per lifetime. The fraction of infections that are
drug sensitive is given by Fw~
Pn
i~1
ciIw,i

P and the fraction that is
drug resistant is Fr~
Pn
i~1
ciIr,i

P. Happenings rates for drug-
sensitive and drug-resistant infections are hw~Fwh and hr~Frh,
respectively.
Acquisition of immunity and parasite clearance
Immunity level (i+1) is assumed to be gained for infected
individuals in immunity level (i) after hi
{1 days. Once individuals
gain immunity at level (i), protection is sustained through re-infection
and is otherwise lost at a rate of ci
{1 days. It is assumed that the rate
at which infections are cleared by drugs is ri~fisi, where si is the
rate at which clinical symptoms arise and fi is the fraction of
infections treated and cleared of parasites. Note that as immunity is
gained, the likeliness that infections lead to clinical symptoms
decreases, such that siwsiz1. We assumed that the natural
clearance rate of an infection by a resistant parasite (kr) is faster
than that of the wild type (kw), i.e., kwvkr. Thus, in the absence of
any drug treatment, the wild-type will always out compete resistance.
Equations
The model is defined by the following set of coupled ordinary
differential equations:
class i~1 :
_S1~B{S1 b
Pn
j~1
cj Iw,jzIr,j
 
zm
 !
zIw,1 r1zkw,1ð ÞzIr,1kr,1zc1S2
_Iw,1~S1b
Pn
j~1
cjIw,j{Iw,1 r1zkw,1zmzmw,1
 
{Iw,1h1
_Ir,1~S1b
Pn
j~1
cjIr,j{Ir,1 kr,1zmzmr,1
 
{Ir,1h1
8>>>>>><
>>>>>>:
classes 1vivn :
_Si~{Si b
Pn
j~1
cj Iw,jzIr,j
 
zmzci{1
 !
zIw,i rizkw,ið ÞzIr,ikr,izciSiz1
_Iw,i~Sib
Pn
j~1
cjIw,k{Iw,i rizkw,izmzmw,i
 
{Iw,ihizIw,i{1hi{1
_Ir,i~Sib
Pn
j~1
cjIr,j{Ir,i kr,izmzmr,i
 
{Ir,ihizIr,i{1hi{1
8>>>>>>><
>>>>>>>:
class i~n :
_Sn~{Sn b
Pn
j~1
cj Iw,jzIr,j
 
zmzcn{1
 !
zIw,n rnzkw,nð ÞzIr,nkr,n
_Iwn~Snb
Pn
j~1
cjIw,j{Iw,n rnzkw,nzmzmw,n
 
zIw,n{1hn{1
_Irn~Snb
Pn
j~1
cjIr,j{Ir,n kr,nzmzmr,n
 
zIr,n{1hn{1
8>>>>>>><
>>>>>>:
ð1Þ
where b~
bV
1zsP
.
Calculating R0
Parasite fitness is calculated as the basic reproductive number
(R0), both for the sensitive ‘wild type’ and for the resistant parasites.
For each immunity class, i, the population was assumed to be
completely susceptible within that class, such that Si&1. The R0 -
values of the sensitive wild type parasites in each immunity class are:
R0 w,ið Þ~
bV ciz
Xn{1
j~iz1
cjYw iz1,jð ÞzcnYw iz1,n{1ð Þ hn{1
rnzkw,nzmzmw,n
 !,
rizkw,izhizmzmw,i
 
for 1ƒivn{1, and:
R0 w,n{1ð Þ~
bV cn{1zcn
hn{1
rnzkw,nzmzmw,n
 
rn{1zkw,n{1zhn{1zmzmw,n{1
 
,
R0 w,nð Þ~bVcn

rnzkw,nzmzmw,n
 
,
where Yw j,ið Þ~P
i
k~j
hk{1
rkzkw,kzhkzmzmw,k
.
Similarly, R0 -values for the resistant parasite:
R0 r,ið Þ~
bV ciz
Xn{1
j~iz1
cjYr iz1,jð ÞzcnYr iz1,n{1ð Þ hn{1
kr,nzmzmw,n
 !,
kr,izhizmzmw,i
 
for 1ƒivn{1, and:
R0 r,n{1ð Þ~
bV cn{1zcn
hn{1
kr,nzmzmw,n
 
kr,n{1zhn{1zmzmw,n{1
 
,
R0 r,nð Þ~bVcn

kr,nzmzmw,n
 
,
where Yr j,ið Þ~P
i
k~j
hk{1
kr,kzhkzmzmw,k
.
It is now possible to determine which of the two parasites will
out-compete the other, by defining the effective reproductive rate
of the sensitive and the resistant parasite, with respect:
Rw~
Xn
i~1
Si
 ! Xn
i~1
fiR0 w,ið Þ
 !
and
Rr~
Xn
i~1
Si
 ! Xn
i~1
fiR0 r,ið Þ
 !
where fi (.0) is the fraction of the population that is in immunity
class i (i.e., fi~SizIw,izIr,i). When RrwRw and Rrw1 the
resistant parasite spreads throughout the population and the
sensitive parasite goes extinct. Thus, assuming that
Pn
i~1
Siw0, we
find the following condition:
ð1Þ
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RrwRw iff
Xn
i~1
fi R0 r,ið Þ{R0 w,ið Þ
 
w0 ð2Þ
Clearly, when all immunity classes fulfill R0 w,ið ÞvR0 r,ið Þ,
condition (2) is held, and if in addition if Rrw1, then the resistant
parasite spreads throughout the population. We note that a
necessary condition for the persistence of either the sensitive or the
resistant parasite is that Rww1 or Rrw1, with respect, however, as
demonstrated, this is not a sufficient condition.
Taking a closer look at condition (2), we see that it can still be
met if only some of the classes fulfill R0 w,ið ÞvR0 r,ið Þ, such that it is
still possible that RrwRw, and this depends on two factors: 1) the
extent of the difference between the R0’s of each class, and 2) the
fraction of the population in each class (fi).
The first factor is determined by the selection pressures acting on
the two types of parasites. For example, when drug pressure is high, as
would be expected for small i’s, then R0 w,ið ÞvR0 r,ið Þ. But when drug
pressure drops in the higher immunity classes due to the reduction in
clinical symptoms, the fitness cost of being resistant may start taking
it’s toll such that R0 w,ið ÞwR0 r,ið Þ. However, in the latest classes, when
the duration of infection is extended, the fitness cost may loose it’s
impact, and again R0 w,ið ÞvR0 r,ið Þ. The difference between the basic
reproductive numbers in each class keeps the same sign, either
negative or positive, regardless of the level of vectorial capacity. When
vectorial capacity is low, most of the population belongs to the classes
of the lowest i’s (see orange curve in Figure 2), and thus, if
R0 w,ið ÞvR0 r,ið Þ in these classes, it is likely that RrwRw. As vectorial
capacity increases, a higher fractions of the population is now in the
higher classes (see green curve in Figure 2), and if R0 w,ið ÞwR0 r,ið Þ in
those classes, it is possible that RrvRw. Similarly, if the vectorial
capacity is even higher, most of the population will be situated in the
highest immunity classes (see blue curve in Figure 2), and if
R0 w,ið ÞvR0 r,ið Þ in these classes, it is possible to return to a case where
RrwRw. An example of such a case can be found in Figure 3.
The 3-class model
Simulations. Simulations were carried out by using a Matlab
ODE solver for the set of equations (1). Similar parameters to those
used by Klein et al. (2008) were chosen, and defined in Table 1.
Note that following Klein et al. (2008), we have assumed that
transmission probabilities decrease with the gain of immunity. It is
however possible that there is higher transmission probabilities in
asymptomatic carriers (see for example, [33], and as we show
further down our results are not sensitive to this assumption.
Necessary conditions for the non linear resistance pattern
in the 3 class model. A necessary condition for the non linear
resistance pattern is for selection to favor the resistant parasite over
the wild type in the first and third immunity classes, while favoring
the wild type over the resistant one in the second immunity class,
such that according to (2): R0 w,1ð ÞvR0 r,1ð Þ, R0 w,2ð ÞwR0 r,2ð Þ and
R0 w,3ð ÞvR0 r,3ð Þ. From the formulation of R0 w,ið Þ and R0 r,1ð Þ above,
we find the following three conditions:
I :
kr,1zh1zmzmr,1
 
r1zkw,1zh1zmzmw,1
 
c1zc2
h1
r2zkw,2zh2zmzmw,2ð Þzc3
h1
r2zkw,2zh2zmzmw,2ð Þ
h2
r3zkw,3zmzmw,3ð Þ
 
crzc2
h1
kr,2zh2zmzmr,2ð Þzc3
h1
kr,2zh2zmzmr,2ð Þ
h2
kr,3zmzmr,3ð Þ
  v1
II :
kr,2zh2zmzmr,2
 
r2zkw,2zh2zmzmw,2
  c2zc3
h2
r3zkw,3zmzmw,3ð Þ
 
c2zc3
h2
kr,3zmzmr,3ð Þ
  w1
III :
kr,3zmzmr,3
 
r3zkw,3zmzmw,3
 v1
From condition III we find that kr,3vr3zkw,3, and thus, for
condition II to hold we must have kr,2wr2zkw,2. From this, in
order for condition I to hold: kr,1vr1zkw,1. Equivalently, we
find that the following three conditions for ‘‘valley phenome-
non’’: y:kw,1vr1,y:kw,2wr2 andy:kw,3vr3, where y such that
1zyð Þkw,i~kr,i:
These conditions highlight three key parameters responsible for
patterns of spread of drug resistance at different vectorial capacities,
the fitness cost on the resistant parasite, the rate that infections are
cleared by drugs and the natural clearance of an infection, y, r and
kw, with respect. Note that these results demonstrate that the
necessary conditions for the valley phenomenon do not depend on
transmission probabilities decreasing or alternatively, increasing
with the gain of clinical immunity, such that these results would hold
both for c1§c2§c3 and for c1ƒc2ƒc3.
Two class Model
Simulations. As before, simulations were carried out using a
Matlab ODE solver for the set of equations (1). Similar parameters
to those used by Klein et al. (2008) were chosen, and defined in
Table 2 (parameters not specified are identical to those in Table 1).
Thresholds in a two-class model. Similarly to Klein et al.
(2008), for the two-class model, the effective R0’s of the sensitive
and resistant parasites are:
Rr~ S1zS2ð Þ f1R0 r,1ð Þzf2R0 r,2ð Þ
 
Rw~ S1zS2ð Þ f1R0 w,1ð Þzf2R0 w,2ð Þ
 
where
Table 1.
B, m Natural human birth and death rate 1/(60*365)
mw,1, mr,1 Disease induced death rate in immunity class 1
(0 for the other classes)
180/100000/365
c1 Loss of immunity rate 1/(3*365)
c2 1/(2*365)
h1 Gain of immunity rate 1/(5*365)
h2 1/(10*365)
r1 Rate at which existing infections are cleared
by drugs (ri~sizi )
zi Fraction of clinical symptoms treated
si Clinical symptoms arise
1/200
r2 1/500
r3 1/500
k1 Natural clearance of infection rate 1/150
k2 1/150
k3 1/400
a Human feeding rate 0.3
B Infectivity rate 0.8
g Instantaneous death rate 1/10
g Number of days required for sporogony 10
c1 Transmission probability 0.7
c2 0.5
c3 0.1
y Fitness cost 0.6
doi:10.1371/journal.pone.0013588.t001
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R0 w,1ð Þ~
bV
h1zr1zkw,1zmzmw,1
c1z
h1c2
r2zkw,2zmzmw,2
 	
,
R0 w,2ð Þ~
bVc2
r2zkw,2zmzmw,2
and
R0 r,1ð Þ~
bV
h1zkr,1zmzmr,1
c1z
h1c2
kr,2zmzmr,2
 	
,
R0 r,2ð Þ~
bVc2
kr,2zmzmr,2
:
By defining:
A~
1
h1zkr,1zmzmr,1
c1z
h1c2
kr,2zmzmr,2
 	
{
1
h1zr1zkw,1zmzmw,1
c1z
h1c2
r2zkw,2zmzmw,2
 	 ð3Þ
and:
B~
c2
r2zkw,2zmzmw,2
{
c2
kr,2zmzmr,2
ð4Þ
we find that if A and B are positive, thenRwwRr iff f2wfc~
A
AzB
.
Thus, when the fraction of the population in the second immunity
class is below this threshold (fc), the resistant parasite out-competes
the sensitive one, and when the fraction is above this threshold, the
sensitive parasite out-competes the resistant. In Figure 5, the dashed
horizontal line notes this threshold (fc) for the specific realization
demonstrated in black. This threshold is calculated according to the
parameters found for this realization with a fitness cost of y~0:5 in
the natural clearance rate of the resistant parasite.
However, if A and B are not both positive we find that (see
Figure 6):
when : Aw0, Bw0 : if f2v
A
AzB
then RrwRw, else RrƒRw
when : Aw0, Bv0 : Vf2 RrwRw
when : Av0, Bv0 : if f2w
A
AzB
then RrwRw, else RrƒRw
and when : Av0, Bw0 : Vf2 RrvRw
From these conditions, it is easy to find that if the fitness cost of
the resistant parasite is smaller than r2=kw,2, this is a necessary and
sufficient condition for B to always negative (see quadrants 3 and 4
in Figure 6). However, the conditions for both A and B to be
negative (quadrants 3 in Figure 6) are that the fitness cost is both
smaller than r2=kw,2 and sufficiently larger than r1=kw1 .
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